GLP1R and chronic kidney disease: If a SGLT2 inhibitor cannot be taken due to a contraindication or drug intolerance, the ADA recommends adding a GLP-1 RA with proven cardiovascular benefit.8 For patients with T2D and CKD (eGFR <60 mL/min/1.73 m2) who do not have albuminuria, the 2022 ADA Standards of Care state that either an SGLT2 inhibitor or GLP-1 RA with proven cardiovascular benefit can be used.